Metformina Aurobindo (Metformin Hydrochloride)

Metformina Aurobindo (metformin hydrochloride) is indicated for conditions related to impaired glucose regulation.

• Type 2 diabetes mellitus: improves glycemic control by lowering fasting and post‑prandial blood glucose.
• Prediabetes (impaired fasting glucose): helps delay progression to diabetes through enhanced insulin sensitivity.
• Polycystic ovary syndrome: reduces insulin resistance, which may improve ovulatory function and hormonal balance.
• Metabolic syndrome: contributes to weight management and improves lipid profile when combined with lifestyle changes.
• Non‑alcoholic fatty liver disease: may improve hepatic insulin sensitivity and reduce liver fat accumulation.

• Metformin hydrochloride acts primarily by inhibiting mitochondrial respiratory‑chain complex I, which decreases hepatic gluconeogenesis. The resulting reduction in hepatic glucose output, together with increased peripheral glucose uptake and enhanced insulin receptor signaling, improves overall insulin sensitivity. Additional effects include modest reduction of intestinal glucose absorption and favorable impacts on lipid metabolism. It does not stimulate insulin secretion, which lowers the risk of hypoglycemia when used as monotherapy.

Metformina Aurobindo may be associated with several adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Gastrointestinal upset: nausea, abdominal discomfort, flatulence, and occasional vomiting, typically occurring early in therapy.
• Diarrhea: loose or watery stools that may be mild to moderate and often improve with dose titration.
• Metallic taste: a transient alteration in taste perception that usually resolves without intervention.
• Decreased appetite: reduced hunger leading to mild weight loss, especially during initial treatment weeks.

Serious or Rare Side Effects

• Lactic acidosis: a rare but life‑threatening accumulation of lactate, presenting with rapid breathing, abdominal pain, and muscle weakness.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, characterized by blistering and widespread rash.
• Hepatotoxicity: significant elevations in liver enzymes or clinical liver injury requiring discontinuation.
• Vitamin B12 deficiency: may develop with long‑term therapy, causing anemia and neuropathy if untreated.

When prescribing Metformina Aurobindo, clinicians should observe several precautionary measures to ensure safe use.

• Renal function: assess eGFR before initiation and monitor periodically, avoiding use in severe renal impairment.
• Hepatic function: evaluate liver enzymes, as impaired function may increase risk of lactic acidosis.
• Cardiovascular status: use cautiously in patients with congestive heart failure or recent myocardial infarction.
• Vitamin B12 levels: monitor during long‑term therapy to detect deficiency early.
• Pregnancy and lactation: avoid unless potential benefits outweigh risks, and discuss with obstetric specialist.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metformina Aurobindo can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Iodinated contrast agents: may precipitate acute renal failure and increase risk of lactic acidosis.
• Cimetidine: can raise metformin plasma concentrations, heightening toxicity risk.
• Alcohol excess: potentiates lactic acidosis, especially in patients with compromised liver function.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may mask hypoglycemia symptoms when combined with insulin secretagogues.
• ACE inhibitors or ARBs: concurrent use can affect renal function, requiring monitoring of kidney parameters.
• Thiazide diuretics: can enhance hypoglycemic effect, necessitating glucose monitoring.
• NSAIDs: may impair renal clearance of metformin, increasing plasma levels.
• Sulfonylureas: combined therapy raises risk of hypoglycemia, requiring dose adjustments.